Doubling down on tumor suppressor deletion
Codeletion of BRCA2 and RB1 increases prostate cancer sensitivity to PARP inhibitor therapy.
Prevalence of homologous recombination deficiency (HRD)-related signatures indicates that a wider range of prostate cancer patients may benefit from PARP-inhibitor therapy
Keyword(s):
2005 ◽
Codeletion of BRCA2 and RB1 increases prostate cancer sensitivity to PARP inhibitor therapy.
